Improving immunotherapy through glycodesign

Matthew J. Buettner, Sagar R. Shah, Christopher T. Saeui, Ryan Ariss, Kevin J Yarema

Research output: Contribution to journalReview article

Abstract

Immunotherapy is revolutionizing health care, with the majority of high impact “drugs” approved in the past decade falling into this category of therapy. Despite considerable success, glycosylation-a key design parameter that ensures safety, optimizes biological response, and influences the pharmacokinetic properties of an immunotherapeutic-has slowed the development of this class of drugs in the past and remains challenging at present. This article describes how optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies. We cover design principles important for early stage pre-clinical development and also discuss how various glycoengineering strategies can augment the biomanufacturing process to ensure the overall effectiveness of immunotherapeutics.

Original languageEnglish (US)
Article number02485
JournalFrontiers in Immunology
Volume9
Issue numberNOV
DOIs
StatePublished - Nov 2 2018

Fingerprint

Glycosylation
Immunotherapy
Cell- and Tissue-Based Therapy
Recombinant Proteins
Pharmaceutical Preparations
Pharmacokinetics
Delivery of Health Care
Safety
Antibodies
Therapeutics

Keywords

  • Antibody-dependent cell cytotoxicity (ADCC)
  • Antibody-drug conjugates (ADCs)
  • Glycoengineering
  • Glycosylation
  • Immunotherapy
  • Metabolic glycoengineering
  • Monoclonal antibodies

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Buettner, M. J., Shah, S. R., Saeui, C. T., Ariss, R., & Yarema, K. J. (2018). Improving immunotherapy through glycodesign. Frontiers in Immunology, 9(NOV), [02485]. https://doi.org/10.3389/fimmu.2018.02485

Improving immunotherapy through glycodesign. / Buettner, Matthew J.; Shah, Sagar R.; Saeui, Christopher T.; Ariss, Ryan; Yarema, Kevin J.

In: Frontiers in Immunology, Vol. 9, No. NOV, 02485, 02.11.2018.

Research output: Contribution to journalReview article

Buettner, MJ, Shah, SR, Saeui, CT, Ariss, R & Yarema, KJ 2018, 'Improving immunotherapy through glycodesign', Frontiers in Immunology, vol. 9, no. NOV, 02485. https://doi.org/10.3389/fimmu.2018.02485
Buettner, Matthew J. ; Shah, Sagar R. ; Saeui, Christopher T. ; Ariss, Ryan ; Yarema, Kevin J. / Improving immunotherapy through glycodesign. In: Frontiers in Immunology. 2018 ; Vol. 9, No. NOV.
@article{b84d7009ec7b4e5eb43138ba3e6ae323,
title = "Improving immunotherapy through glycodesign",
abstract = "Immunotherapy is revolutionizing health care, with the majority of high impact “drugs” approved in the past decade falling into this category of therapy. Despite considerable success, glycosylation-a key design parameter that ensures safety, optimizes biological response, and influences the pharmacokinetic properties of an immunotherapeutic-has slowed the development of this class of drugs in the past and remains challenging at present. This article describes how optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies. We cover design principles important for early stage pre-clinical development and also discuss how various glycoengineering strategies can augment the biomanufacturing process to ensure the overall effectiveness of immunotherapeutics.",
keywords = "Antibody-dependent cell cytotoxicity (ADCC), Antibody-drug conjugates (ADCs), Glycoengineering, Glycosylation, Immunotherapy, Metabolic glycoengineering, Monoclonal antibodies",
author = "Buettner, {Matthew J.} and Shah, {Sagar R.} and Saeui, {Christopher T.} and Ryan Ariss and Yarema, {Kevin J}",
year = "2018",
month = "11",
day = "2",
doi = "10.3389/fimmu.2018.02485",
language = "English (US)",
volume = "9",
journal = "Frontiers in Immunology",
issn = "1664-3224",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - Improving immunotherapy through glycodesign

AU - Buettner, Matthew J.

AU - Shah, Sagar R.

AU - Saeui, Christopher T.

AU - Ariss, Ryan

AU - Yarema, Kevin J

PY - 2018/11/2

Y1 - 2018/11/2

N2 - Immunotherapy is revolutionizing health care, with the majority of high impact “drugs” approved in the past decade falling into this category of therapy. Despite considerable success, glycosylation-a key design parameter that ensures safety, optimizes biological response, and influences the pharmacokinetic properties of an immunotherapeutic-has slowed the development of this class of drugs in the past and remains challenging at present. This article describes how optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies. We cover design principles important for early stage pre-clinical development and also discuss how various glycoengineering strategies can augment the biomanufacturing process to ensure the overall effectiveness of immunotherapeutics.

AB - Immunotherapy is revolutionizing health care, with the majority of high impact “drugs” approved in the past decade falling into this category of therapy. Despite considerable success, glycosylation-a key design parameter that ensures safety, optimizes biological response, and influences the pharmacokinetic properties of an immunotherapeutic-has slowed the development of this class of drugs in the past and remains challenging at present. This article describes how optimizing glycosylation through a variety of glycoengineering strategies provides enticing opportunities to not only avoid past pitfalls, but also to substantially improve immunotherapies including antibodies and recombinant proteins, and cell-based therapies. We cover design principles important for early stage pre-clinical development and also discuss how various glycoengineering strategies can augment the biomanufacturing process to ensure the overall effectiveness of immunotherapeutics.

KW - Antibody-dependent cell cytotoxicity (ADCC)

KW - Antibody-drug conjugates (ADCs)

KW - Glycoengineering

KW - Glycosylation

KW - Immunotherapy

KW - Metabolic glycoengineering

KW - Monoclonal antibodies

UR - http://www.scopus.com/inward/record.url?scp=85056328421&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056328421&partnerID=8YFLogxK

U2 - 10.3389/fimmu.2018.02485

DO - 10.3389/fimmu.2018.02485

M3 - Review article

C2 - 30450094

AN - SCOPUS:85056328421

VL - 9

JO - Frontiers in Immunology

JF - Frontiers in Immunology

SN - 1664-3224

IS - NOV

M1 - 02485

ER -